Eli Lilly cuts money prices of Zepbound weight reduction drug vials

Eli Lilly on Monday said it’s lowering the money prices of single-dose vials of its blockbuster weight reduction drug Zepbound on its direct-to-consumer platform, LillyDirect, constructing on efforts by the corporate and the Trump administration to make the drugs more accessible.

The announcement also comes weeks after chief rival Novo Nordisk unveiled additional discounts on the money prices of its obesity and diabetes drugs. 

Starting Monday, cash-paying patients with a sound prescription can get the starting dose of Zepbound vials for as little as $299 per 30 days on LillyDirect, down from a previous price of $349 per 30 days. They may access the subsequent dose, 5 milligrams, for $399 per 30 days and all other doses for $449 per 30 days, down from $499 per 30 days across those sizes. 

Zepbound carries an inventory price of roughly $1,086 per 30 days. That price point, and spotty insurance coverage for weight reduction drugs within the U.S., have been significant barriers to access for some patients. 

Eli Lilly’s announcement comes just weeks after President Donald Trump inked deals with Eli Lilly and Novo Nordisk to make their GLP-1 drugs easier for Americans to get and afford. The agreements will cut the costs the federal government pays for the drugs, introduce Medicare coverage of obesity drugs for the primary time for certain patients and offer discounted medicines on the federal government’s recent direct-to-consumer website launching in January, TrumpRx. 

But Eli Lilly’s take care of Trump centers around lowering the costs of a distinct type of Zepbound – a multi-dose pen – after it wins Food and Drug Administration approval. 

Which means Eli Lilly’s Monday announcement around cutting prices on the prevailing single-dose vials could allow more patients to get discounted treatments more quickly. 

“We’ll keep working to offer more options — expanding decisions for delivery devices and creating recent pathways for access — so more people can get the medicines they need,” said Ilya Yuffa, president of Lilly USA and global customer capabilities, in an announcement. 

Eli Lilly’s stock, which has climbed greater than 36% this yr, fell nearly 2% on Monday. Its meteoric rise because of the success of Zepbound and its diabetes injection Mounjaro vaulted it to becoming the primary health-care company to hit a $1 trillion market value last month. Though cutting prices means lower revenue per medication sold, Eli Lilly’s sales — and shares — have continued to soar through past pricing announcements as demand balloons.

With single-dose vials, patients need to make use of a syringe and needle to attract up the drugs and inject it into themselves. Eli Lilly first introduced that type of Zepbound in August 2024. 

It’s unclear what number of patients are currently using single-dose vials of Zepbound. But Eli Lilly previously said that direct-to-consumer sales now account for greater than a 3rd of recent prescriptions of Zepbound. 

Novo Nordisk earlier this month lowered the worth of its obesity drug Wegovy and diabetes treatment Ozempic for existing cash-paying patients to $349 per 30 days from $499 per 30 days. That excludes the very best dose of Ozempic. 

The corporate also launched a brief introductory offer, which is able to allow recent cash-paying patients to access the 2 lowest doses of Wegovy and Ozempic for $199 per 30 days for the primary two months of treatment.